The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It the results are good they will have plenty of options on how to go forward.. obv one is a placing, but i can only see a placing with an II and not us.. 25-30% dilution at £1.20 wont be such a bad thing as long as the news is great and we will be moving forward at a much quicker pace
Someone loading up at this level as NT To buy again. Strong support here...it’s looking like the bulls might have it :)))
I would imagine that if / when a placing is to come about it will be designed to allow a long term partner/pharma to take a big stake in the company.
Pure speculation but that would not surprise me in the least ....
Nolupus - Same page here I think, partner waiting in the wings to accelerate this into P3 as part of a licensing deal.
They want COPD data to decide if they want the license for the drug as a whole or just specific to treatment.
Davethedumplin, I was just thinking the same, I don't mind just as long as it is after the results
my guess is that if successful they might need it for distribution logistic purposes.
Of course someone might want a slice of the action and provide the necessary funds.
Yes GHia ....
Regulatory strategy..... P3 or ...
Supply chain .... production logistics ...
What is not said is financing :-)
If I was a betting person , I would put a few quid on the likelihood that negociations are very much ongoing and that due diligence is requiring the readout on COPD ....
Pure positive ramping on my part of course
Nolupus - This section?
“Over the coming months we will have three major clinical trial read-outs for SNG001, our wholly-owned, inhaled IFN-beta asset: COPD patients with regular seasonal viruses; COVID-19 hospital-treated patients; and the early treatment of COVID-19 patients in the home setting. The Company is active on many fronts from designing and managing novel trials to developing the regulatory strategy and supply chain for potential demand in the future."
Supports your theory for readout order:
1. COPD
2. Hospital
3. Home
“Regulatory Strategy and Supply Chain for potential demand in the future”
It’s a nice statement that. The COPD readout must be part of that regulatory strategy.
Well those placing shares will be long gone now anyway...very strong support at 45p level....fundamentally nothing changed here, it’s just a big dip that’s caused panic selling. The sp has nearly halved from the highs...a great entry point
Iglu - think the placing was 35p.
GHia,
Interim analysis is regurally done during trials by the DSMB , so nothing new on that front if we go by the RNS , apart from the unplanned part...
It's RIchard's commentary on the readout which is getting my interest
Looks like the 21k will show up after hrs
The dirty dogs took it down to support from the 18th March...technically we should move up now..GLA
Being trying to buy a few different shares for around an hour. Is there a problem with the market in general?
Still waiting for my buys to show on L2
Same issue nt to buy on hl for a while now.
Unable to buy...NT people loading up now. Wasn’t this the placing price 45p.? Should rise up nicely from here
Nolupus - Embrace the positivity!!
You are right though it’s always worth trying to see both sides, which is why you are a very valuable contributor to the board even if you do pose some very vague questions sometimes.
There is nothing obviously negative about reading COPD early definitely something pushing this decision.
Almost as if one or several interested parties want to see as much data as possible so they can accurately value what’s on offer...
Ghia.,
I am not implying anything ....
I am trying like most intelligent , handsome , open minded people to figure out the logic for this unplanned event :-)
We can only use sound logic to speculate on the reason and therefore the consequences on our investment .
I as usual will be trying to see both sides of the coin but so far I can only come up with one side and that bugs me :-)
Positive side is that someone outside SYN has motivated this change of plan
Just added another 10k & 21k, hopefully tomorrow will see a bounce
Strong buy now
Way oversold....just like DDDD yesterday and look what happened today. I’ve taken a few down here. Seller must nearly be done
Nolupus - Are you implying that they will plan to launch a larger Phase 3 Trial which rather than targeting COPD or Covid 19 could encompass a wide range of viral ailments?
Hence reading COPD data at the same time as Covid data would back up the design of the phase 3 trial?
Things are definitely happening behind the scenes, hopefully the outcome will be good
Ghia,
Read between the lines ... Sng had to apply for autorisation to change the plan on this trial ....
Read carefully the RNS
Nolupus - Unfortunately we can only speculate as to the reasonings.
Initially they had hoped to adjust the COPD trial to allow COVID patients with COPD to take part but this never got amended.
Perhaps during the process of applying to amend the trial they where given the opportunity to do an interim analysis which they had not thought would be on the table?